CPI-455
|
C419976-100mg
|
≥98% |
1628208-23-0 |
100mg
|
¥ 6487.9
|
现货 |
阿拉丁 |
LJH685
|
L413860-25mg
|
≥98% |
1627710-50-2 |
25mg
|
¥ 559.9
|
现货 |
阿拉丁 |
LJH685
|
L413860-100mg
|
≥98% |
1627710-50-2 |
100mg
|
¥ 1966.9
|
现货 |
阿拉丁 |
AZD3759
|
A413895-5g
|
Moligand™, ≥99% |
1626387-80-1 |
5g
|
¥ 2023.9
|
期货,请咨询 |
阿拉丁 |
AZD3759
|
A413895-500mg
|
Moligand™, ≥99% |
1626387-80-1 |
500mg
|
¥ 322.9
|
现货 |
阿拉丁 |
AZD3759
|
A413895-25mg
|
Moligand™, ≥99% |
1626387-80-1 |
25mg
|
¥ 34.9
|
现货 |
阿拉丁 |
AZD3759
|
A413895-1g
|
Moligand™, ≥99% |
1626387-80-1 |
1g
|
¥ 574.9
|
期货,请咨询 |
阿拉丁 |
反式-4-氨基-L-脯氨酸
|
A342472-50mg
|
≥98% |
16257-88-8 |
50mg
|
¥ 411.9
|
期货,请咨询 |
阿拉丁 |
反式-4-氨基-L-脯氨酸
|
A342472-1g
|
≥98% |
16257-88-8 |
1g
|
¥ 4943.9
|
期货,请咨询 |
阿拉丁 |
MQAE [1-(乙氧羰基甲基)-6-甲氧基喹啉溴化物]
|
M131144-1g
|
适用于荧光分析, ≥97% |
162558-52-3 |
1g
|
¥ 2674.9
|
期货,请咨询 |
阿拉丁 |
VR23
|
V413876-50mg
|
≥98% |
1624602-30-7 |
50mg
|
¥ 2687.9
|
现货 |
阿拉丁 |
VR23
|
V413876-10mg
|
≥98% |
1624602-30-7 |
10mg
|
¥ 740.9
|
现货 |
阿拉丁 |
VR23
|
V413876-100mg
|
≥98% |
1624602-30-7 |
100mg
|
¥ 4541.9
|
现货 |
阿拉丁 |
N-2-萘基-N'-[2-氧代-2-(1-吡咯烷基)乙基]脲
|
X412226-50mg
|
≥98% |
1624117-53-8 |
50mg
|
¥ 2755.9
|
期货,请咨询 |
阿拉丁 |
N-2-萘基-N'-[2-氧代-2-(1-吡咯烷基)乙基]脲
|
X412226-1mg
|
≥98% |
1624117-53-8 |
1mg
|
¥ 129.9
|
现货 |
阿拉丁 |
N-2-萘基-N'-[2-氧代-2-(1-吡咯烷基)乙基]脲
|
X412226-10mg
|
≥98% |
1624117-53-8 |
10mg
|
¥ 500.9
|
现货 |
阿拉丁 |
N-2-萘基-N'-[2-氧代-2-(1-吡咯烷基)乙基]脲
|
X412226-100mg
|
≥98% |
1624117-53-8 |
100mg
|
¥ 5386.9
|
期货,请咨询 |
阿拉丁 |
Remodelin hydrobromide
|
R413800-25mg
|
≥98% |
1622921-15-6 |
25mg
|
¥ 1019.9
|
现货 |
阿拉丁 |
Remodelin hydrobromide
|
R413800-100mg
|
≥98% |
1622921-15-6 |
100mg
|
¥ 3604.9
|
现货 |
阿拉丁 |
地美司钠
|
D275705-250mg
|
≥98% |
16208-51-8 |
250mg
|
¥ 196.9
|
现货 |
阿拉丁 |
地美司钠
|
D275705-1g
|
≥98% |
16208-51-8 |
1g
|
¥ 500.9
|
现货 |
阿拉丁 |
2-甲基-6-(三氟甲基)吡啶
|
M174636-5g
|
≥97% |
1620-72-0 |
5g
|
¥ 749.9
|
现货 |
阿拉丁 |
2-甲基-6-(三氟甲基)吡啶
|
M174636-10g
|
≥97% |
1620-72-0 |
10g
|
¥ 1424.9
|
现货 |
阿拉丁 |
UNC0379
|
U413785-50mg
|
≥97% |
1620401-82-2 |
50mg
|
¥ 2317.9
|
现货 |
阿拉丁 |